Revelation Biosciences, Inc. (REVB) Sets 1-for-7 Reverse Split Effective Oct 20, 2026
Revelation Biosciences (REVB) will execute a 1-for-7 reverse stock split on Oct 20, 2026, to meet Nasdaq's minimum bid price requirement. The company aims to comply with listing standards, with shares trading under a new CUSIP post-split.
How this was made

The 30-second read
Why it matters
The split could temporarily boost the share price, but long‑term performance hinges on upcoming trial data or financing.
Market read
A compliance‑driven corporate action with modest short‑term trading relevance for REVB holders.
What to watch
Future clinical or financing milestones will be needed to sustain any price gains post‑split.
Background
Revelation Biosciences is a small‑cap biotech currently below Nasdaq's $1 minimum bid price, prompting the reverse split.
Ticker impact
Announcement of a 1-for-7 reverse stock split to regain Nasdaq minimum bid price compliance.
likely modest upward pressure as the post‑split price meets compliance thresholds
Reverse splits are typically viewed as a compliance move; the market may price in a short‑term bounce but long‑term impact depends on subsequent milestones.
Market effects
May signal compliance pressure for other small‑cap biotech stocks on Nasdaq.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact; primarily a micro‑cap corporate action.
Counterpoint
Some investors may view the split as a red flag and short the stock despite compliance intent.
Key entities
- companyRevelation Biosciences, Inc.
Biotech firm executing a reverse split to meet Nasdaq listing standards.


